注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Oncternal Therapeutics Inc是一家臨床階段的生物製藥公司。該公司專注於開發腫瘤療法,用於治療具有嚴重未滿足醫療需求的癌症患者。該公司的候選產品包括Zilovertamab、ONCT-808、ONCT-534和ONCT-216。Zilovertamab是一種研究性人源化單克隆抗體,旨在抑制受體酪氨酸激酶樣孤兒受體1(ROR1),這是一種在許多腫瘤上表達的生長因子受體,可激活增加腫瘤增殖、侵襲性和耐藥性的途徑,並結合到ROR1的特定功能重要表位。ONCT-808是一種靶向ROR1的自體嵌合抗原受體(CAR-T)療法,用於治療血液系統惡性腫瘤和實體瘤。ONCT-534是一種雙重作用雄激素受體抑製劑(DAARI),用於治療晚期去勢抵抗性前列腺癌(CRPC)和其他雄激素受體(AR)驅動的疾病。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
David F. Hale | 75 | 2019 | Independent Chairman of the Board |
Daniel L. Kisner | 77 | 2019 | Independent Director |
Thomas Kipps | - | - | Scientific Advisor |
Robert James Wills | 70 | 2019 | Non-Independent Director |
Xin Nakanishi | 62 | 2019 | Independent Director |
Gunnar F. Kaufmann | 47 | 2019 | Prostate Cancer & Cell Therapy Scientific Advisory Board Member |
Charles P. Theuer | 60 | 2019 | Independent Director |
James B. Breitmeyer | 70 | 2019 | President, CEO & Director |
Michael G. Carter | 86 | 2006 | Independent Director |
William R. LaRue | 73 | 2019 | Independent Director |
Angela Shen | - | 2021 | Cell Therapy Scientific Advisory Board Member |
Jill M. DeSimone | 68 | 2023 | Independent Director |
Rosemary Mazanet | 68 | 2021 | Independent Director |
Sadik Kassim | 43 | 2021 | Cell Therapy Scientific Advisory Board Member |
Michael Wang | - | 2021 | Cell Therapy Scientific Advisory Board Member |
Johann De Bono | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Marcela V. Maus | 47 | 2021 | Cell Therapy Scientific Advisory Board Member |
Evan Ya-Wen Yu | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Matthew R. Smith | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Howard R. Soule | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Scott Dehm | - | 2023 | Prostate Cancer Scientific Advisory Board Member |
Ramesh Narayanan | - | 2023 | Scientific Advisors |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核